Ifitm3 Found To Be Critical Regulator Of Immunotherapy Sensitivity In Small Cell Lung Cancer

New investigation presented identifies interferon-induced transmembrane macromolecule 3 (IFITM3) arsenic a captious regulator of immunotherapy sensitivity successful mini compartment lung crab (SCLC), offering a promising caller avenue for overcoming guidance to PD-1/PD-L1 checkpoint blockade.

The investigation was presented astatine nan International Association for nan Study of Lung Cancer 2025 World Conference connected Lung Cancer (WCLC).

SCLC tumors are typically characterized by debased look of awesome histocompatibility analyzable people I (MHC-I), which impairs immune nickname and response. Researchers from nan Shanghai Pulmonary Hospital and nan University of Pittsburgh person discovered that IFITM3 enhances MHC-I look by activating NLRC5, a cardinal transcriptional regulator, and promoting its atomic translocation. This effect improves antigen position and boosts CD8⁺ T compartment infiltration and cytotoxicity.

Our study shows that IFITM3 plays a pivotal domiciled successful shaping tumor immunogenicity successful SCLC. It whitethorn service some arsenic a predictive biomarker for immunotherapy consequence and a caller therapeutic target."

Dr. Xinyu Liu of Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

Dr. Liu presented a number of important findings:

• Strong relationship betwixt IFITM3 and MHC-I look successful aggregate real-world SCLC cohorts.
• IFITM3 overexpression upregulated antigen position pathways and accrued CD8⁺ T compartment infiltration.
• IFITM3 look predicted improved progression-free endurance successful patients receiving chemoimmunotherapy.
• A caller compound, ethyl gallate (EG), induced IFITM3 and sensitized tumors to PD-1 blockade successful preclinical models.

"Our study suggests that pharmacological induction of IFITM3 could correspond a caller strategy to amended objective outcomes for patients pinch SCLC. Future objective investigation whitethorn validate IFITM3 arsenic some a biomarker and a therapeutic adjunct to existent immunotherapy regimens," Dr. Liu reported.